Humacyte Announces Symvess is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs

- Surgical Implant – Next Generation contract makes Symvess more easily accessible to 170 VA hospitals –

- SAC awards require intensive product and value analysis vetting by a surgical committee and streamline the approval process by individual hospitals -

DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that Symvess is now under contract with the with Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs (VA). The SAC SING (Surgical Implant – Next Generation) contract makes Symvess more easily accessible to 170 VA hospitals as the SAC system is the preferred and primary sourcing vehicle for VA hospitals. SAC awards require intensive product and value analysis vetting by a surgical committee and streamline the approval process by individual hospitals, making Symvess more readily available and visible across the entire VA system.

“We are pleased that Symvess is now under contract with the Strategic Acquisition Center, making the first-in-class product accessible to healthcare professionals treating military veterans,” said Dr. Laura Niklason, President and CEO of Humacyte, Inc. “SAC is the preferred sourcing vehicle for the VA, and we anticipate that the SAC SING contract will expedite our ability to respond to interest from surgeons operating in the VA system.”

Symvess (acellular tissue engineered vessel-tyod) was approved in the extremity vascular trauma indication by the Food and Drug Administration (FDA) in December 2024. For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for use or sale by the FDA or any other regulatory agency.

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing an innovative biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues designed to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Schreibe Deinen Kommentar